Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California.
J Nucl Med. 2013 Dec;54(12):2055-61. doi: 10.2967/jnumed.113.123257. Epub 2013 Oct 21.
Planning hepatic (90)Y radioembolization activity requires balancing toxicity with efficacy. We developed a dual-tracer SPECT fusion imaging protocol that merges data on radioactivity distribution with physiologic liver mapping.
Twenty-five patients with colorectal carcinoma and bilobar liver metastases received whole-liver radioembolization with resin microspheres prescribed as per convention (mean administered activity, 1.69 GBq). As part of standard treatment planning, all patients underwent SPECT imaging after intraarterial injection of 37 MBq of (99m)Tc-macroaggregated albumin ((99m)Tc-MAA) to simulate subsequent (90)Y distribution. Immediately afterward, patients received 185 MBq of labeled sulfur colloid ((99m)Tc-SC) intravenously as a biomarker for normal hepatic reticuloendothelial function and SPECT was repeated. The SPECT images were coregistered and fused. A region-based method was used to predict the (90)Y radiation absorbed dose to functional liver tissue (DFL) by calculation of (99m)Tc-MAA activity in regions with (99m)Tc-SC uptake. Similarly, the absorbed dose to tumor (DT) was predicted by calculation of (99m)Tc-MAA activity in voxels without (99m)Tc-SC uptake. Laboratory data and radiographic response were measured for 3 mo, and the survival of patients was recorded. SPECT-based DT and DFL were correlated with parameters of toxicity and efficacy.
Toxicity, as measured by increase in serum liver enzymes, correlated significantly with SPECT-based calculation of DFL at all time points (P < 0.05) (mean DFL, 27.9 Gy). Broad biochemical toxicity (>50% increase in all liver enzymes) occurred at a DFL of 24.5 Gy and above. In addition, in uni- and multivariate analysis, SPECT-based calculation of DT (mean DT, 44.2 Gy) correlated with radiographic response (P < 0.001), decrease in serum carcinoembryonic antigen (P < 0.05), and overall survival (P < 0.01). The cutoff value of DT for prediction of 1-y survival was 55 Gy (area under the receiver-operating-characteristic curve = 0.86; P < 0.01). Patients who received a DT of more than 55 Gy had a median survival of 32.8 mo, compared with 7.2 mo in patients who received less (P < 0.05).
Dual-tracer (99m)Tc-MAA-(99m)Tc-SC fusion SPECT offers a physiology-based imaging tool with significant prognostic power that may lead to improved personalized activity planning.
规划肝脏 90Y 放射性栓塞活动需要在疗效和毒性之间取得平衡。我们开发了一种双示踪剂 SPECT 融合成像方案,该方案将放射性分布数据与生理肝脏绘图相结合。
25 例结直肠癌伴双叶肝转移患者接受树脂微球全肝放射性栓塞治疗,按常规方案规定(平均给予活度 1.69GBq)。作为标准治疗计划的一部分,所有患者在经动脉注射 37MBq(99m)Tc-聚合白蛋白((99m)Tc-MAA)后进行 SPECT 成像,以模拟随后的 90Y 分布。之后立即静脉注射 185MBq 标记的硫胶体((99m)Tc-SC)作为正常肝网状内皮功能的生物标志物,并重复 SPECT。对 SPECT 图像进行配准和融合。使用基于区域的方法,通过计算(99m)Tc-MAA 在(99m)Tc-SC 摄取区域的活性,预测功能性肝组织(DFL)的 90Y 吸收剂量。同样,通过计算(99m)Tc-MAA 在无(99m)Tc-SC 摄取的体素中的活性来预测肿瘤(DT)的吸收剂量。对患者进行 3 个月的实验室数据和影像学反应测量,并记录患者的生存情况。SPECT 预测的 DT 和 DFL 与毒性和疗效参数相关。
以血清肝酶升高为指标的毒性与各时间点的 SPECT 预测 DFL 显著相关(P < 0.05)(平均 DFL 为 27.9Gy)。在 DFL 大于 24.5Gy 时出现广泛的生化毒性(所有肝酶增加超过 50%)。此外,在单变量和多变量分析中,SPECT 预测的 DT(平均 DT 为 44.2Gy)与影像学反应(P < 0.001)、血清癌胚抗原下降(P < 0.05)和总生存时间(P < 0.01)相关。DT 的预测 1 年生存率的截断值为 55Gy(受试者工作特征曲线下面积=0.86;P < 0.01)。接受 DT 大于 55Gy 的患者中位生存期为 32.8 个月,而接受 DT 小于 55Gy 的患者中位生存期为 7.2 个月(P < 0.05)。
双示踪剂(99m)Tc-MAA-(99m)Tc-SC 融合 SPECT 提供了一种具有显著预后能力的基于生理学的成像工具,可能导致更个性化的活动规划。